Cat. No. 2195
Chemical Name: α-(4-Chlorophenyl)-4-[(4-fluoropheny
Biological ActivityNon-competitive NMDA receptor antagonist that acts at the polyamine modulatory site. Selective for NR2B- over NR2A- and NR2C-containing receptors (IC50 values are 1, > 100 and > 100 μM respectively). Also σ1 ligand (Ki = 0.013 μM). Antagonizes neuronal voltage-gated Ca2+ channels and selectively inhibits the rapid component of the delayed rectifier K+ current (IKr). Neuroprotective.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Lengyel et al (2004) Effect of a neuroprotective drug, eliprodil on cardiac repolarisation: importance of the decreased repolarisation reserve in the development of proarrhythmic risk. Br.J.Pharmacol. 143 152. PMID: 15302678.
Whittemore et al (1997) Antagonism of N-methyl-D-aspartate receptors by σ site ligands: potency, subtype-selectivity and mechanisms of inhibition. J.Pharmacol.Exp.Ther. 282 326. PMID: 9223571.
Bath et al (1996) The effects of ifenprodil and eliprodil on voltage-dependent Ca2+ channels and in gerbil global cerebral ischaemia. Eur.J.Pharmacol. 299 103. PMID: 8901012.
If you know of a relevant reference for this product please let us know.
View Related Products by Product Action
Keywords: Eliprodil, supplier, σ, sigma, ligands, σ1, sigma1, σ2, sigma2, polyamine, site, NMDA, antagonists, Ca2+, channel, blockers, Neuroprotective, Non-competitive, NR2B-selective, Receptors, Glutamate, N-Methyl-D-Aspartate, iGluR, Ionotropic, Tocris Bioscience, NMDA Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Potent NMDA receptor antagonist; NR2A selectivecis-6-Hydroxynorketamine hydrochloride
Metabolite of ketamine (Cat.No. 3131); antidepressive
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.